Ron Brooks, M.S., is an acclaimed expert in analytical instrumentation and laboratory operations, with a deep focus on the cannabis industry. His extensive experience spans over a decade, during which he has spearheaded initiatives to improve safety, compliance, and operational ... efficiency. Ron's career is marked by notable leadership roles at leading cannabis testing facilities in California, as well as his years of clinical laboratory support and advising. Since 2015, under his guidance, Ron Brooks Consulting LLC excels in providing top-tier consulting, advisory, and training services, aiming to shape the future of cannabis safety testing. His recent work includes assisting companies in obtaining laboratory licenses and launching testing operations in Alabama, Mississippi, and New York. Ron's influence extends beyond business achievements. In 2023, he was invited to testify before the New Hampshire Commission on cannabis legislation and safety, at the request of Governor Sununu, showcasing his expertise and commitment to public safety in the cannabis sector. An active member of the scientific community, Ron serves on the Editorial Board for Cannabis and Cannabinoid Research. His advice is sought after by elected officials on cannabis safety testing, underlining his authority in the field. Ron's educational background includes a Bachelor of Arts in Biology from the historic Transylvania University and a Master of Science in Biology from Eastern Kentucky University.

Brian McNally, PhD is a Vice President at Kx Advisors and is based in Washington, DC. Brian brings his deep expertise in diagnostics and life sciences to create tailored growth strategies for his clients. He specializes in corporate strategy, product development, market sizing ... and forecasting, and commercial strategy. Prior to joining Kx, Brian founded Expansome, a boutique consultancy focused on life sciences and diagnostics startups. Earlier in his career, Brian served in various marketing and product development roles at Canon BioMedical and Qiagen. Brian earned his PhD in Cell and Molecular Biology from the University of Texas Southwestern and BS in Biological Sciences from Carnegie Mellon University.

Jieli Shirley Li, MD, PhD, holds the position of Associate Professor-Clinical in the Department of Pathology and serves as Co-Director of the Clinical Chemistry & Toxicology Laboratory. Dr. Li obtained her MD and PhD degrees from the Shanghai Jiao-Tong University School of ... Medicine and completed her fellowship training in clinical chemistry at the MD Anderson Cancer Center. Her professional interests center around enhancing laboratory tests for the in vitro diagnosis, prognosis, and treatment planning of cancer, endocrine disorders, and cardiovascular diseases. Dr. Li has authored over 40 scientific articles and contributing as an Ad Hoc reviewer for 20 different scientific journals. She also plays a vital role in participating in guidelines writing for the Clinical & Laboratory Standards Institute (CLSI) and serving on the Expert Panel Committee of CLSI. Furthermore, Dr. Li contributes to the field as an inspector for the College of American Pathologists (CAP) and is actively involved with CAP's Chemistry Committee. In addition to her contributions to the field, Dr. Li is an integral part of the Advances in Clinical Chemistry Education and New Technology (ACCENT®) Review Board, Abstract Review Board, and serves as the Chair of the Ohio Valley Local Section for the Association for Diagnostics & Laboratory Medicine (ADLM).

Linda Hasadsri is the Director of the Molecular Technologies Laboratory and the Chair of Equity, Inclusion, and Diversity for the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota. She completed her MS in Genetic Counseling at California State ... University Northridge, followed by dual MD & PhD degrees at the University of Illinois Urbana-Champaign, and finally two fellowships in Clinical Biochemical and Clinical Molecular Genetics at Mayo Clinic. She has since worked at Mayo as a board certified clinical lab director for 8 years. Her areas of expertise include the laboratory diagnosis of inborn errors of metabolism, mitochondrial disease, cystic fibrosis, carrier screening, hereditary amyloidoses, hemoglobinopathies, and hereditary epigenomics.

Dr. Shi earned her doctoral degree from the University of British Columbia in Canada, and subsequently completed a Clinical Chemistry fellowship at the University of Washington Medical Center in the United States. She holds both American and Canadian board certifications in ... Clinical Chemistry. Dr. Shi serves as a clinical biochemist at Vancouver General Hospital and the discipline lead of the tumor marker laboratory. During her training, Dr. Shi developed a strong interest in clinical proteomics, focusing on harnessing the potential of mass spectrometry for the quantitative analysis of large molecules in clinical applications. She actively contributes to knowledge translation through presentations at ADLM (formerly AACC) and MSACL. Her clinical research work, involving the mass spectrometric analysis of thyroglobulin and ACTH, has been published in the Journal of Mass Spectrometry and Clinical Chemistry and Clinical Chemistry, respectively.

Dr. Matthew Lafrenière is currently a staff Clinical Biochemist at Sunnybrook Health Sciences Center (SHSC). He completed a postdoctoral training program in Clinical Biochemistry at McMaster University in June 2022 and obtained a PhD at the National Research Council of Canada ... and the University of Ottawa, where he received an NSERC-CREATE Training Program in Medicinal Chemistry and Biopharmaceutical Development. After successful completion of his PhD, he taught as a professor at the University of Ottawa's Department of Chemistry and Biomolecular Sciences.

Xuehai Wang is the scientific director of the clinical flow cytometry lab at BC Cancer and a clinical assistant professor in the Department of Pathology and Laboratory Medicine at The University of British Columbia. After completing his postdoctoral training, he transitioned from ... basic research to applied clinical research, where he led the development of complex immunophenotyping assays and automated analytical pipelines in the clinical lab. His research focuses on 1) developing machine learning tools to automate flow cytometry data analysis and 2) Characterize systemic immune perturbations during immunotherapy.